U.S. Food and Drug Administration (FDA) recently accepted the Biologics License Application (BLA) for RP1 plus nivolumab in advanced melanoma for ...
Proceeds expected to fund the start of the ALG-000184 Phase 2 clinical studyFunding expected to extend cash runway into the second half of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback